Literature DB >> 20551156

Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study.

A G Semb1, T K Kvien, A H Aastveit, I Jungner, T R Pedersen, G Walldius, I Holme.   

Abstract

OBJECTIVES: To examine the rates of acute myocardial infarction (AMI) and ischaemic stroke (IS) and to examine the predictive value of total cholesterol (TC) and triglycerides (TG) for AMI and IS in patients with rheumatoid arthritis (RA) and people without RA.
METHODS: In the Apolipoprotein MOrtality RISk (AMORIS) Study 480 406 people (including 1779 with RA, of whom 214 had an AMI and 165 an IS) were followed for 11.8 (range 7-17) years. Cox regression analysis was used to calculate HR per SD increase in TC or TG with 95% CI. All values were adjusted for age, diabetes and hypertension.
RESULTS: The levels of TC and TG were significantly lower in patients with RA than in people without RA. Despite this, the rate of AMI and IS per 1000 years was at least 1.6 times higher in RA than non-RA. TC was nearly significantly predictive for AMI (HR/SD 1.13 (95% CI 0.99 to 1.29), p=0.07) and significantly predictive for future IS in RA (HR/SD 1.20 (95% CI 1.03 to 1.40), p=0.02). TG had no relationship to development of AMI (1.07, 0.94 to 1.21, p=0.29), but was weakly related to IS (1.13, 0.99 to 1.27, p=0.06). In contrast, both TC and TG were significant predictors of AMI and IS in people without RA.
CONCLUSIONS: Patients with RA had 1.6 times higher rate of AMI and IS than people without RA. TC and TG were significant predictors of AMI and IS in people without RA, whereas the predictive value in RA was not consistent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551156     DOI: 10.1136/ard.2009.126128

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  53 in total

Review 1.  My treatment approach to rheumatoid arthritis.

Authors:  John M Davis; Eric L Matteson
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

Review 2.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 3.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

Review 4.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

Review 5.  Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.

Authors:  Matxalen Amezaga Urruela; Maria E Suarez-Almazor
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

6.  Positive effect of hydroxychloroquine on lipid profiles of patients with rheumatoid arthritis: A Veterans Affair cohort.

Authors:  Myriam Guevara; Bernard Ng
Journal:  Eur J Rheumatol       Date:  2020-11-05

Review 7.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 8.  [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis].

Authors:  S Kleinert; K Krueger
Journal:  Z Rheumatol       Date:  2011-08       Impact factor: 1.372

9.  Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Authors:  Katherine P Liao; Jun Liu; Bing Lu; Daniel H Solomon; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

Review 10.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.